AN2 Therapeutics Inc (ANTX)
2.005
-0.12
(-5.42%)
USD |
NASDAQ |
May 23, 16:00
2.005
0.00 (0.00%)
After-Hours: 17:18
AN2 Therapeutics Free Cash Flow (Quarterly): -17.59M for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -17.59M |
| December 31, 2023 | -17.07M |
| September 30, 2023 | -11.80M |
| June 30, 2023 | -12.82M |
| March 31, 2023 | -11.60M |
| December 31, 2022 | -7.638M |
| September 30, 2022 | -9.487M |
| Date | Value |
|---|---|
| June 30, 2022 | -9.595M |
| March 31, 2022 | -6.742M |
| December 31, 2021 | -8.993M |
| September 30, 2021 | -4.691M |
| June 30, 2021 | -5.257M |
| March 31, 2021 | -1.543M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-17.59M
Minimum
Mar 2024
-1.543M
Maximum
Mar 2021
-9.602M
Average
-9.487M
Median
Sep 2022
Free Cash Flow (Quarterly) Benchmarks
| Revance Therapeutics Inc | -71.11M |
| Viking Therapeutics Inc | -6.134M |
| VYNE Therapeutics Inc | -7.982M |
| Aquestive Therapeutics Inc | -10.41M |
| Humacyte Inc | -27.74M |